CTLA4 expression is an indicator and regulator of steady-state CD4+FoxP3+ T cell homeostasis

被引:87
作者
Tang, Anita L. [1 ]
Teijaro, John R. [1 ]
Njau, Modesta N. [1 ]
Chandran, Smita S. [1 ]
Azimzadeh, Agnes [1 ]
Nadler, Steven G. [2 ]
Rothstein, David M. [3 ]
Farber, Donna L. [1 ]
机构
[1] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA
[2] Bristol Myers Squibb Co, Res & Dev, Immunol & Inflammat Drug Discovery, Princeton, NJ 08543 USA
[3] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA
关键词
D O I
10.4049/jimmunol.181.3.1806
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The presence of FoxP3(+) regulatory T cells (Tregs) is necessary for control of deleterious immune responses in the steady state; however, mechanisms for maintaining the frequency and quality of endogenous Tregs are not well defined. In this study, we used in vivo modulators of the CD28 and CTLA4 pathways administered to intact mice to reveal mechanisms controlling the homeostasis and phenotype of endogenous Tregs. We demonstrate that expression of the negative costimulatory regulator CTLA4 on FoxP3(+) Tregs in vivo is a direct consequence of their rapid, perpetual homeostasis. Up-regulation of CTLA4 expression occurs only on FoxP3(+) Tregs undergoing extensive proliferation and can be abrogated by inhibiting the CD28 pathway, coinciding with a reduction in FoxP3(+) Treg proliferation and frequency. We further demonstrate that CTLA4 negatively regulates steady-state Treg homeostasis, given that inhibiting CTLA4 signaling with an anti-CTLA4 blocking Ab greatly enhances Treg proliferation and overall Treg frequency. Our findings provide new insight into the origin and role of CTLA4 expression on natural FoxP3(+) Tregs and reveal opposing effects of costimulation modulators on the steady-state level and quality of Tregs, with implications regarding their effects on endogenous Tregs inpatients receiving immunotherapy.
引用
收藏
页码:1806 / 1813
页数:8
相关论文
共 54 条
[1]  
Ahmadzadeh M, 1999, J IMMUNOL, V163, P3053
[2]  
Alegre ML, 1996, J IMMUNOL, V157, P4762
[3]   Cutting edge: Transplantation tolerance through enhanced CTLA-4 expression [J].
Ariyan, C ;
Salvalaggio, P ;
Fecteau, S ;
Deng, SY ;
Rogozinski, L ;
Mandelbrot, D ;
Sharpe, A ;
Sayegh, MH ;
Basadonna, GP ;
Rothstein, DM .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :5673-5677
[4]   Association of CTLA4 polymorphism with regulatory T cell frequency [J].
Atabani, SF ;
Thio, CL ;
Divanovic, S ;
Trompette, A ;
Belkaid, Y ;
Thomas, DL ;
Karp, CL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (07) :2157-2162
[5]   CTLA4IG PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED-IMMUNITY [J].
BALIGA, P ;
CHAVIN, KD ;
QIN, LH ;
WOODWARD, J ;
LIN, JX ;
LINSLEY, PS ;
BROMBERG, JS .
TRANSPLANTATION, 1994, 58 (10) :1082-1090
[6]   Natural regulatory T cells in infectious disease [J].
Belkaid, Y ;
Rouse, BT .
NATURE IMMUNOLOGY, 2005, 6 (04) :353-360
[7]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[8]   CTLA41g: Bridging the basic immunology with clinical application [J].
Bluestone, JA ;
St Clair, EW ;
Turka, LA .
IMMUNITY, 2006, 24 (03) :233-238
[9]  
Boden Elisa, 2003, Novartis Found Symp, V252, P55
[10]   CD28 COSTIMULATION CAN PROMOTE T-CELL SURVIVAL BY ENHANCING THE EXPRESSION OF BCL-X(L) [J].
BOISE, LH ;
MINN, AJ ;
NOEL, PJ ;
JUNE, CH ;
ACCAVITTI, MA ;
LINDSTEN, T ;
THOMPSON, CB .
IMMUNITY, 1995, 3 (01) :87-98